ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non ‐small cell lung cancer

In this study, we also summarized previously reported cases and concluded thatALK rearrangement is a rare but critical resistance mechanism to osimertinib. After failure of combined treatment with osimertinib plus crizotinib, comprehensive molecular profiling should be performed, and chemotherapy plus bevacizumab might be an optimal treatment especially for patients harboringVEGFA amplification.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research